# A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants

> **NCT02337764** · PHASE3 · COMPLETED · sponsor: **Takeda** · enrollment: 222 (actual)

## Conditions studied

- Parkinson's Disease

## Interventions

- **DRUG:** TVP-1012 1mg

## Key facts

- **NCT ID:** NCT02337764
- **Lead sponsor:** Takeda
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-02-03
- **Primary completion:** 2016-09-29
- **Final completion:** 2016-09-29
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2022-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02337764

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02337764, "A Long-term, Phase 3 Study of TVP-1012 (1 mg) in Levodopa Treated Parkinson's Disease Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02337764. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*